论文部分内容阅读
OBJECTIVE The aim of this study was to investigate Mrna expression of tyrosine-kinase receptors (TRKs) and neurotrophins (NTs) in human neuroblastomas.METHODS Expression of TrkA, TrkB, TrkC and BDNF was quantitatively examined by reverse transcription-polymerase chain reaction (RT-PCR)in 27 cases of neuroblastomas.RESULTS The high and total rates of TrkA were expressed in significantly more tumors in a lower-stage group compared to a higher-stage group (P＜0.05) and the high level of TrkA expression was correlated positively with the 2-year cumulative-survival rate of the patients (P＜0.01). The high and total rates of TrkB were expressed in significantly more tumors in a higher-stage group compared to a lower-stage group (P＜0.05). All 3 rates of BDNF expression between the 2 groups showed no statistical difference (P＞0.05), but the co-expression ratio of TrkB and BDNF showed a remarkable significance in the higher-stage group more than in the lower-stage group (P＜0.05). TrkC expression was usually accompanied by TrkA expression, but there was only a non-significant trend between TrkC expression and TrkA expression.CONCLUSION RT-PCR for Mrna expression of TRKs and NTs has important clinical significance relating to the tumor stage and outcome for patients with neuroblastomas.